Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs such as thalidomide may stop the growth of cancer cells by stopping blood
flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating women who have
epithelial ovarian cancer that has not responded to previous therapy.